KEVEYIS

LOE Approaching

dichlorphenamide

NDAORALTABLET

Approved

Jul 1958

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Data completeness

5/8 — Partial

KEVEYIS (dichlorphenamide) is carbonic anhydrase inhibitors [moa]. Approved for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, related variants (). First approved in 1958.

Drug data last refreshed 3d ago · AI intelligence enriched 3w ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

KEVEYIS (dichlorphenamide) is an oral carbonic anhydrase inhibitor approved in 1958 for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, as well as related variants. It works by inhibiting carbonic anhydrase, an enzyme critical to ion transport regulation, thereby reducing the frequency and severity of paralytic episodes. KEVEYIS is the primary therapeutic option for these rare channelopathies and represents a niche but essential treatment for a limited patient population.

$0.0BPart D

Mechanism of Action

Carbonic Anhydrase Inhibitors

Pharmacologic Class:

Carbonic Anhydrase Inhibitor

Indications (3)

primary hyperkalemic periodic paralysis primary hypokalemic periodic paralysis

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pro Feature

Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Career Relevance

KEVEYIS creates specialized roles for rare disease brand managers, medical science liaisons (MSLs) with neurology/genetics expertise, and field teams focused on neurology specialists and rare disease centers. Success in this space requires deep knowledge of channelopathies, clinical trial design in orphan populations, and payer expertise in rare disease coverage. Currently, zero open positions are linked to this product in the available dataset, reflecting the niche, stable nature of the market.

External Resources

Official Product Website

Patient information & support programs

ClinicalTrials.gov

Active clinical trials for this drug

DailyMed

Full prescribing information

FDA Drugs@FDA

FDA approval history

RxNorm

Drug nomenclature & identifiers